Skip to main content
SpringerLink
Log in
Book cover

The Metabolic Syndrome pp 37–55Cite as

The Role of Obesity in Insulin Resistance

Epidemiological and Metabolic Aspects

  • Chapter

  • 1539 Accesses

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Obesity is a rapidly growing health problem in the United States. In 2000, about 20% of U.S. adults self-reported a body mass index (BMI) exceeding 30 kg/m2, a 61% increase in obesity since 1991 (1). This underestimates the real prevalence when body mass index is determined from direct measurements rather than self-report. More than half (56%) reported being at least overweight (BMI ≥25 kg/m2), up from 45% in 1991. Lifetime risk for overweight during the 1990s was approximately 50% for overweight and 25% for obesity in a representative U.S. sample (2). Obesity confers substantial excess risk for morbidity and mortality from a variety of associated conditions, especially type 2 diabetes and atherosclerotic cardiovascular disease (CVD) (3–5). Although overall body fatness, as measured by BMI, is clearly associated with mortality and complications of obesity (6), fat distribution, especially central fatness as measured by a large waist circumference, may be a more powerful correlate of risk associated with obesity, especially for type 2 diabetes and CVD (7–9).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286:1195–1200.

    Article  CAS  PubMed  Google Scholar 

  2. Vasan RS, Pencina MJ, Cobain M, Freiberg MS, O’Agostino RB. Estimated risks for developing obesity in the Framingham Heart Study. Ann Intern Med 2005; 143:473–480.

    PubMed  Google Scholar 

  3. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991–1998. JAMA 1999; 282:1519–1522.

    Article  CAS  PubMed  Google Scholar 

  4. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427–434.

    Article  CAS  PubMed  Google Scholar 

  5. Haslam DW, James WP. Obesity. Lancet 2005; 366:1197–1209.

    Article  PubMed  Google Scholar 

  6. Manson JE, Skerrett PJ, Greenland P, VanItallie TB. The escalating pandemics of obesity and sedentary lifestyle: A call to action for clinicians. Arch Intern Med 2004; 164:249–258.

    Article  PubMed  Google Scholar 

  7. Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord 2001; 25:1047–1056.

    Article  CAS  PubMed  Google Scholar 

  8. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE. Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280:1843–1848.

    Article  CAS  PubMed  Google Scholar 

  9. Wei M, Gaskill SP, Haffner SM, Stern MP. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waistlhip ratio and other anthropometric measurements in Mexican Americans: A 7-year prospective study. Obes Res 1997; 5:16–23.

    CAS  PubMed  Google Scholar 

  10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon OJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: An American Heart AssociationlNational Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005.

    Google Scholar 

  11. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity: European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997; 100:1166–1173.

    Article  CAS  PubMed  Google Scholar 

  12. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595–1607.

    Article  CAS  PubMed  Google Scholar 

  13. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54:3252–3257.

    Article  CAS  PubMed  Google Scholar 

  14. Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien P-J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952–957.

    Article  CAS  PubMed  Google Scholar 

  15. Bonora E, Tessari R, Micciolo R, Zenere M, Targher G, Padovani R, Falezza G, Muggeo M. Intimalmedial thickness of the carotid artery in nondiabetic and NIDDM patients: Relationship with insulin resistance. Diabetes Care 1997; 20:627–631.

    Article  CAS  PubMed  Google Scholar 

  16. Wilson PWF, Kannel WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Archives of Internal Medicine 1999; 159:1104–1109.

    Article  CAS  PubMed  Google Scholar 

  17. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stem MP. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 1992; 41:715–722.

    Article  CAS  PubMed  Google Scholar 

  18. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: A new worldwide definition. Lancet 2005; 366:1059–1062.

    Article  PubMed  Google Scholar 

  19. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16:442–443.

    Article  CAS  PubMed  Google Scholar 

  20. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539–553.

    Article  CAS  PubMed  Google Scholar 

  21. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9:237–252.

    PubMed  Google Scholar 

  22. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356–359.

    Article  PubMed  Google Scholar 

  23. St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal-weight Americans: New definition of the metabolically obese, normal-weight individual. Diabetes Care 2004; 27:2222–2228.

    Article  PubMed  Google Scholar 

  24. Wilson PWF, D’Agostino Sr RB, Parise H, Sullivan L, Meigs JB. The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112:3066–3072.

    Article  CAS  PubMed  Google Scholar 

  25. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27:2444–2449.

    Article  PubMed  Google Scholar 

  26. Yarnell JW, Patterson CC, Bainton D, Sweetnam PM. Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies. Heart 1998; 79:248–252.

    CAS  PubMed  Google Scholar 

  27. Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism 1996; 45:699–706.

    Article  CAS  PubMed  Google Scholar 

  28. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders. Diabetes 1998; 47:16431649.

    Article  Google Scholar 

  29. Liese AD, Mayer-Davis EJ, Tyroler HA, Davis CE, Keil U, Duncan BB, Heiss G. Development of the multiple metabolic syndrome in the ARIC cohort-joint contribution of insulin, BMI, and WHR: Atherosclerosis risk in communities. Ann Epidemiol 7:407–416, 1997.

    Article  CAS  PubMed  Google Scholar 

  30. Palaniappan L, Carnethon MR, Wang Y, Hanley AJ, Fortmann SP, Haffner SM, Wagenknecht L. Predictors of the incident metabolic syndrome in adults: The Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27:788–793.

    Article  PubMed  Google Scholar 

  31. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53:2087–2094.

    Article  CAS  PubMed  Google Scholar 

  32. Fox CS, Massaro JM, Hoffmann U, Horvat PM, Vasan RS, Meigs JB, O’Donnell CJ. Volumetric assessment of visceral and subcutaneous adipose tissue compartments and association with metabolic risk factors: The Framingham Heart Study. Circulation 2006; 113.

    Google Scholar 

  33. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI, Kahn BB. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001; 409:729–733.

    Article  CAS  PubMed  Google Scholar 

  34. Saltiel AR. You are what you secrete. Nat Med 2001; 7:887–888.

    Article  CAS  PubMed  Google Scholar 

  35. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32(suppl 3):1423.

    Google Scholar 

  36. Frayn KN. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001; 60:375–380.

    Article  CAS  PubMed  Google Scholar 

  37. Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001; 50(suppl 1):S118–121.

    Article  Google Scholar 

  38. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46:3–10.

    Article  CAS  PubMed  Google Scholar 

  39. Paolisso G, Gualdiero P, Manzella D, Rizzo MR, Tagliamonte MR, Gambardella A, Verza M, Gentile S, Varricchio M, D’Onofrio F. Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients. American Journal of Cardiology 1997; 80:932–937.

    Article  CAS  PubMed  Google Scholar 

  40. Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans: European Group for the Study of Insulin Resistance (EGIR). Eur J Clin Invest 2000; 30:45–52.

    Article  CAS  PubMed  Google Scholar 

  41. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97:2859–2865.

    Article  CAS  PubMed  Google Scholar 

  42. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106:171–176.

    Article  CAS  PubMed  Google Scholar 

  43. Hotamisligil GS, Spiegelman BM. TNF-alpha: A key component of obesity-diabetes link. Diabetes 1994; 43:1271–1278.

    Article  CAS  PubMed  Google Scholar 

  44. Paolisso G, Rizzo MR, Mazziotti G, Tagliamonte MR, Gambardella A, Rotondi M, Carella C, Giugliano D, Varricchio M, D’Onofrio F. Advancing age and insulin resistance: Role of plasma tumor necrosis factor-alpha. American Journal of Physiology 1998; 38:E294–E299.

    Google Scholar 

  45. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997; 100:1230–1239.

    Article  CAS  PubMed  Google Scholar 

  46. Balletshofer BM, Rittig K, Yolk A, Maerker E, Jacob S, Rett K, Haring H. Impaired non-esterified fatty acid suppression is associated with endothelial dysfunction in insulin resistant subjects. Horm Metab Res 2001; 33:428–431.

    Article  CAS  PubMed  Google Scholar 

  47. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000; 49:1231–1238.

    Article  CAS  PubMed  Google Scholar 

  48. Lind L, Fugmann A, Branth S, Vessby B, Millgard J, Berne C, Lithell H. The impairment in endothelial function induced by non-esterified fatty acids can be reversed by insulin. Clin Sci (Lond) 2000; 99:169–174.

    Article  CAS  Google Scholar 

  49. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45:623–634.

    Article  CAS  PubMed  Google Scholar 

  50. Yudkin JS, Stehouwer CDA, Emis JJ, Coppack SW. C-reactive protein in healthy subjects-associations with obesity, insulin resistance and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arteriosclerosis, Thrombosis and Vascular Biology 1999; 19:972–978.

    CAS  Google Scholar 

  51. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796–1808.

    CAS  PubMed  Google Scholar 

  52. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821–1830.

    CAS  PubMed  Google Scholar 

  53. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993; 259:87–91.

    Article  CAS  PubMed  Google Scholar 

  54. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95:2409–2415.

    Article  CAS  PubMed  Google Scholar 

  55. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF-alpha by human muscle: Relationship to insulin resistance. J Clin Invest 1996; 97:1111–1116.

    Article  CAS  PubMed  Google Scholar 

  56. Mantzoros CS, Moschos S, Avramopoulos I, Kaklamani V, Liolios A, Doulgerakis DE, Griveas I, Katsilambros N, Flier JS. Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans. J Clin Endocrinol & Metab 1997; 82:3408–3413.

    Article  CAS  Google Scholar 

  57. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, Yano Y. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol & Metab 1998; 83:859–862.

    Article  CAS  Google Scholar 

  58. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol & Metab 1999; 84:272–278.

    Article  CAS  Google Scholar 

  59. Lofgren P, van Harmelen V, Reynisdottir S, Naslund E, Ryden M, Rossner S, Arner P. Secretion of tumor necrosis factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue. Diabetes 2000; 49:688–692.

    Article  CAS  PubMed  Google Scholar 

  60. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology 1998; 18:1199–1202.

    CAS  PubMed  Google Scholar 

  61. Desfaits A, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care 1998; 21:487–493.

    Article  CAS  PubMed  Google Scholar 

  62. Winkler G, Salamon F, Salamon D, Speer G, Simon K, Cseh K. Elevated serum tumor necrosis factor-alpha levels contribute to the insulin resistance in type II (non-insulin-dependent) diabetes and in obesity. Diabetologia 1998; 41:860–861.

    Article  CAS  PubMed  Google Scholar 

  63. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207–214.

    Article  CAS  PubMed  Google Scholar 

  64. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448–454.

    Article  CAS  PubMed  Google Scholar 

  65. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol & Metab 1997; 82:4196–4200.

    Article  CAS  Google Scholar 

  66. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated c-reactive protein levels in overweight and obese adults. JAMA 1999; 282(22):2131–2135.

    Article  CAS  PubMed  Google Scholar 

  67. Ford ES. Body mass index, diabetes and c-reactive protein among U.S. adults. Diabetes Care 1999; 22(12):1971–1977.

    Article  CAS  PubMed  Google Scholar 

  68. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of c-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arteriosclerosis, Thrombosis and Vascular Biology 1999; 19:1986–1991.

    CAS  Google Scholar 

  69. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W. Association between C-reactive protein and features of the metabolic syndrome: A populationbased study. Diabetes Care 2000; 23:1835–1839.

    Article  CAS  PubMed  Google Scholar 

  70. Festa A, D’Agostino Jr R, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001; 25:1407–1415.

    Article  CAS  PubMed  Google Scholar 

  71. Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58:1703–1710.

    Article  CAS  PubMed  Google Scholar 

  72. Festa A, D’Agostino R, Jr., Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102:42–47.

    CAS  PubMed  Google Scholar 

  73. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord 2001; 25:1416–1420.

    Article  CAS  PubMed  Google Scholar 

  74. Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: The Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 2002; 155:65–71.

    Article  PubMed  Google Scholar 

  75. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40:1286–1292.

    Article  CAS  PubMed  Google Scholar 

  76. Grau AJ, Buggle F, Becher H, Werle E, Hacke W. The association of leukocyte count, fibrinogen, and c-reactive protein with vascular disease risk factors and ischemic vascular diseases. Thrombosis Research 1996; 82:245–255.

    Article  CAS  PubMed  Google Scholar 

  77. McMillan DE. Increased levels of acute-phase serum proteins in diabetes. Metabolism 1989; 38:1042–1046.

    Article  CAS  PubMed  Google Scholar 

  78. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9:414–417.

    Article  CAS  PubMed  Google Scholar 

  79. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340:115–126.

    Article  CAS  PubMed  Google Scholar 

  80. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351:2599–2610.

    Article  CAS  PubMed  Google Scholar 

  81. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363–369.

    Article  PubMed  Google Scholar 

  82. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286:327–334.

    Article  CAS  PubMed  Google Scholar 

  83. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study. Diabetes 2001; 50:2384–2389.

    Article  CAS  PubMed  Google Scholar 

  84. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study. Lancet 1999; 353:1649–1652.

    Article  CAS  PubMed  Google Scholar 

  85. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Blair SN. White blood cell count as a novel predictor of type 2 diabetes. Diabetes 1998; 47:0101.

    Google Scholar 

  86. Lindsay RS, Krakoff J, Hanson RL, Bennett PH, Knowler WC. Gamma globulin levels predict type 2 diabetes in the Pima Indian population. Diabetes 2001; 50:1598–1603.

    Article  CAS  PubMed  Google Scholar 

  87. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53:693–700.

    Article  CAS  PubMed  Google Scholar 

  88. Festa A, D’ Agostino R, Jr., Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes 2002; 51:1131–1137.

    Article  CAS  PubMed  Google Scholar 

  89. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293:1673–1677.

    Article  CAS  PubMed  Google Scholar 

  90. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108:437–446.

    CAS  PubMed  Google Scholar 

  91. Reid J, MacDougall AI, Andrews MM. Aspirin and diabetes mellitus. Brit Med J 1957; 2:1071–1074.

    Article  CAS  PubMed  Google Scholar 

  92. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104:787–794.

    Article  CAS  PubMed  Google Scholar 

  93. Meigs JB, Wilson PWF, Tofler GH, Fox CS, Nathan DM, D’Agostino Sr. RB, O’Donnell CJ. Markers of endothelial dysfunction predict incident type 2 diabetes. Diabetes 2005; 54(suppl 1):A90.

    Google Scholar 

  94. Wexler DJ, Hu FB, Manson JE, Rifai N, Meigs JB. Mediating effects of inflammatory biomarkers on insulin resistance associated with obesity. Obes Res 2005; 13:1772–1783.

    Article  CAS  PubMed  Google Scholar 

  95. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79–83.

    Article  CAS  PubMed  Google Scholar 

  96. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930–1935.

    Article  CAS  PubMed  Google Scholar 

  97. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: Leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13:51–59.

    Article  CAS  PubMed  Google Scholar 

  98. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D’Armiento M, D’Andrea F, Giugliano D. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial. JAMA 2004; 292:1440–1446.

    Article  CAS  PubMed  Google Scholar 

  99. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25:376–380.

    Article  CAS  PubMed  Google Scholar 

  100. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86:3815–3819.

    Article  CAS  PubMed  Google Scholar 

  101. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121–2134.

    Article  CAS  PubMed  Google Scholar 

  102. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98:2005–2010.

    Article  CAS  PubMed  Google Scholar 

  103. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8:1288–1295.

    Article  CAS  PubMed  Google Scholar 

  104. Hara K, Yamauchi T, Kadowaki T. Adiponectin: An adipokine linking adipocytes and type 2 diabetes in humans. Curr Diab Rep 2005; 5:136–140.

    Article  CAS  PubMed  Google Scholar 

  105. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270:26746–26749.

    Article  CAS  PubMed  Google Scholar 

  106. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100:2473–2476.

    CAS  PubMed  Google Scholar 

  107. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102:1296–1301.

    CAS  PubMed  Google Scholar 

  108. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103:1057–1063.

    CAS  PubMed  Google Scholar 

  109. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941–946.

    Article  CAS  PubMed  Google Scholar 

  110. Lam KS, Xu A. Adiponectin: Protection of the endothelium. Curr Diab Rep 2005; 5:254–259.

    Article  CAS  PubMed  Google Scholar 

  111. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006; 55:249–259.

    Article  CAS  PubMed  Google Scholar 

  112. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360:57–58.

    Article  CAS  PubMed  Google Scholar 

  113. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361:226–228.

    Article  CAS  PubMed  Google Scholar 

  114. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Tominaga M, Kato T. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: The Funagata study. Diabetes Care 2003; 26:2015–2020.

    Article  CAS  PubMed  Google Scholar 

  115. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730–1737.

    Article  CAS  PubMed  Google Scholar 

  116. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409:307–312.

    Article  CAS  PubMed  Google Scholar 

  117. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002; 13:18–23.

    Article  CAS  PubMed  Google Scholar 

  118. Banerjee RR, Lazar MA. Resistin: Molecular history and prognosis. J Mol Med 2003; 81:218–226.

    CAS  PubMed  Google Scholar 

  119. Ukkola O. Resistin: A mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 2002; 147:571–574.

    Article  CAS  PubMed  Google Scholar 

  120. Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance: The emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001; 345:1345–1346.

    Article  CAS  PubMed  Google Scholar 

  121. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O’Rahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50:2199–2202.

    Article  CAS  PubMed  Google Scholar 

  122. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285:561–564.

    Article  CAS  PubMed  Google Scholar 

  123. Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003; 300:674–678.

    Article  CAS  PubMed  Google Scholar 

  124. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359:46–47.

    Article  CAS  PubMed  Google Scholar 

  125. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11:997–1001.

    Article  CAS  PubMed  Google Scholar 

  126. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: Correlations with insulin resistance. Eur J Endocrinol 2003; 149:331–335.

    Article  CAS  PubMed  Google Scholar 

  127. McTernan PG, Fisher PM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S. Resistin and type 2 diabetes: Regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003; 88:6098–6106.

    Article  CAS  PubMed  Google Scholar 

  128. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88:5452–5455.

    Article  CAS  PubMed  Google Scholar 

  129. Fehmann HC, Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm Metab Res 2002; 34:671–673.

    Article  CAS  PubMed  Google Scholar 

  130. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88:4848–4856.

    Article  CAS  PubMed  Google Scholar 

  131. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, Xiao Q, Mistry JS, Retzlaff BM, Knopp RH, Kahn SE. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005; 48:2330–2333.

    Article  CAS  PubMed  Google Scholar 

  132. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27:2450–2457.

    Article  CAS  PubMed  Google Scholar 

  133. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003; 108:2054–2059.

    Article  PubMed  Google Scholar 

  134. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: Cause of the insulin resistance syndrome. Diabetes 1997; 46 Suppl 2:S9–13.

    Google Scholar 

  135. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48:1856–1862.

    Article  CAS  PubMed  Google Scholar 

  136. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291:1978–1986.

    Article  CAS  PubMed  Google Scholar 

  137. Meigs JB, O’Donnell C J, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D’Agostino RB, Wilson PW. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: The Framingham Offspring Study. Diabetes 2006; 55:530–537.

    Article  CAS  PubMed  Google Scholar 

  138. Clark MG, Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, Rattigan S. Blood flow and muscle metabolism: A focus on insulin action. Am J Physiol Endocrinol Metab 2003; 284:E241–258.

    CAS  PubMed  Google Scholar 

  139. Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation 2005; 111:363–368.

    Article  PubMed  Google Scholar 

  140. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340:319–323.

    Article  CAS  PubMed  Google Scholar 

  141. Hogikyan RV, Galecki AT, Pitt B, Halter JB, Greene DA, Supiano MA. Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. J Clin Endocrinol & Metab 1998; 83:1946–1952.

    Article  CAS  Google Scholar 

  142. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D’Agostino RB, Wilson PWF. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 2000; 283:221–228.

    Article  CAS  PubMed  Google Scholar 

  143. Vehkavaara S, Seppala-Lindroos A, Westerbacka J, Groop P-H, Yki-Jarvinen H. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 1999; 22:205–52060.

    Article  Google Scholar 

  144. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101:1780–1784.

    CAS  PubMed  Google Scholar 

  145. Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002; 161:233–242.

    Article  CAS  PubMed  Google Scholar 

  146. Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper DJ, Klein BE, Hubbard LD, Duncan BB. Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA 2002; 287:2528–2533.

    Article  PubMed  Google Scholar 

  147. Rossi R, Cioni E, Nuzzo A, Origliani G, Modena MG. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care 2005; 28:702–707.

    Article  PubMed  Google Scholar 

  148. Kanaya AM, Wassel Fyr C, Vittinghoff E, Harris TB, Park SW, Goodpaster BH, Tylavsky F, Cummings SR. Adipocytokines and incident diabetes mellitus in older adults: The independent effect of plasminogen activator inhibitor 1. Arch Intern Med 2006; 166:350–356.

    Article  CAS  PubMed  Google Scholar 

  149. Holmlund A, Hulthe J, Millgard J, Sarabi M, Kahan T, Lind L. Soluble intercellular adhesion molecule-I is related to endothelial vasodilatory function in healthy individuals. Atherosclerosis 2002; 165:271–276.

    Article  CAS  PubMed  Google Scholar 

  150. Agewall S. Insulin sensitivity and haemostatic factors in men at high and low cardiovascular risk: The Risk Factor Intervention Study Group. J Intern Med 1999; 246:489–495.

    Article  CAS  PubMed  Google Scholar 

  151. Baron AD. Cardiovascular actions of insulin in humans: Implications for insulin sensitivity and vascular tone. In: Anonymous Insulin Resistance, Ferrannini E (ed.), Bailliere Tindall, London, 1994, pp. 961–985.

    Google Scholar 

  152. Bonadonna RC, Saccomani MP, Del Prato S, Bonora E, DeFronzo RA, Cobelli C. Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation 1998; 98:234–241.

    CAS  PubMed  Google Scholar 

  153. Serne EH, RG IJ, Gans RO, Nijveldt R, De Vries G, Evertz R, Donker AJ, Stehouwer CD. Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes 2002; 51:1515–1522.

    Article  CAS  PubMed  Google Scholar 

  154. Henstridge DC, Kingwell BA, Formosa MF, Drew BG, McConell GK, Duffy SJ. Effects of the nitric oxide donor, sodium nitroprusside, on resting leg glucose uptake in patients with type 2 diabetes. Diabetologia 2005; 48:2602–2608.

    Article  CAS  PubMed  Google Scholar 

  155. Miles PD, Levisetti M, Reichart D, Khoursheed M, Moossa AR, Olefsky JM. Kinetics of insulin action in vivo: Identification of rate-limiting steps. Diabetes 1995; 44:947–953.

    Article  CAS  PubMed  Google Scholar 

  156. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B, Scherrer U. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001; 104:342–345.

    CAS  PubMed  Google Scholar 

  157. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001; 7:1138–1143.

    Article  CAS  PubMed  Google Scholar 

  158. Monti LD, Barlassina C, Citterio L, Galluccio E, Berzuini C, Setola E, Valsecchi G, Lucotti P, Pozza G, Bernardinelli L, Casari G, Piatti P. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. Diabetes 2003; 52:1270–1275.

    Article  CAS  PubMed  Google Scholar 

  159. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37:1344–1350.

    Article  CAS  PubMed  Google Scholar 

  160. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27:484–490.

    Article  CAS  PubMed  Google Scholar 

  161. Diabetes Prevention Program: Prevention of type 2 diabetes with Troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54:1150–1156.

    Google Scholar 

  162. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87:563–568.

    Article  CAS  PubMed  Google Scholar 

  163. O’Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999; 33:1506–1511.

    Article  PubMed  Google Scholar 

  164. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103:357–362.

    CAS  PubMed  Google Scholar 

  165. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B. Ramipril and the development of diabetes. JAMA 2001; 286:1882–1885.

    Article  CAS  PubMed  Google Scholar 

  166. Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: A mechanism linking insulin resistance to vascular disease. Lancet 2005; 365:1817–1820.

    Article  PubMed  Google Scholar 

  167. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: A prospective study of men and women. Circulation 2005; 112:505–512.

    Article  PubMed  Google Scholar 

  168. Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN. Metabolic syndrome, obesity, and mortality: Impact of cardiorespiratory fitness. Diabetes Care 2005; 28:391–397.

    Article  PubMed  Google Scholar 

  169. Wei M, Gibbons LW, MItchell TL, Kampert JB, Lee CD, Blair SN. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes in men. Ann Int Med 1999; 130:89–96.

    CAS  PubMed  Google Scholar 

  170. Blair SN, Kampert JB, Kohl HW, 3rd, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA 1996; 276:205–210.

    Article  CAS  PubMed  Google Scholar 

  171. Sesso HD, Paffenbarger RS Jr, Lee IM. Physical activity and coronary heart disease in men: The Harvard Alumni Health Study. Circulation 2000; 102:975–980.

    CAS  PubMed  Google Scholar 

  172. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345:790–797.

    Article  CAS  PubMed  Google Scholar 

  173. Kris-Etherton P, Eckel RH, Howard BV, St Jeor S, Bazzarre TL. AHA Science Advisory—Lyon Diet Heart Study: Benefits of a Mediterranean-style, National Cholesterol Education Programl American Heart Association step I dietary pattern on cardiovascular disease. Circulation 2001; 103:1823–1825.

    CAS  PubMed  Google Scholar 

  174. Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F. Beneficial effects of a dietary approach to stop hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005; 28:2823–2831.

    Article  CAS  PubMed  Google Scholar 

  175. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PW, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004; 27:538–546.

    Article  PubMed  Google Scholar 

  176. Schulze MB, Hoffmann K, Manson JE, Willett WC, Meigs JB, Weikert C, Heidemann C, Colditz GA, Hu FB. Dietary pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr 2005; 82:675–684; quiz 714–675.

    CAS  PubMed  Google Scholar 

  177. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142:611–619.

    CAS  PubMed  Google Scholar 

  178. Ilanne-Parikka P, Eriksson JG, Lindstrom J, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Rastas M, Salminen V, Aunola S, Sundvall J, Valle T, Lahtela J, Uusitupa M, Tuomilehto J. Prevalence of the metabolic syndrome and its components: Findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care 2004; 27:2135–2140.

    Article  PubMed  Google Scholar 

  179. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289:2560–2572.

    Article  CAS  PubMed  Google Scholar 

  180. National Cholesterol Education Program: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.

    Google Scholar 

  181. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393–403.

    Article  CAS  PubMed  Google Scholar 

  182. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854–865.

    Google Scholar 

  183. Davidson MB. Is treatment of insulin resistance beneficial independent of glycemia? Diabetes Care 2003; 26:3184–3186.

    Article  PubMed  Google Scholar 

  184. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106–1118.

    Article  PubMed  Google Scholar 

  185. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164:2097–2104.

    Article  CAS  PubMed  Google Scholar 

  186. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679–684.

    Article  CAS  PubMed  Google Scholar 

  187. Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004; 27:1349–1357.

    Article  CAS  PubMed  Google Scholar 

  188. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24:930–934.

    Article  CAS  PubMed  Google Scholar 

  189. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial. Lancet 2005; 366:1279–1289.

    Article  CAS  PubMed  Google Scholar 

  190. Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003; 26:3148–3152.

    Article  CAS  PubMed  Google Scholar 

  191. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: One-year experience from the RIO-Europe study. Lancet 2005; 365:1389–1397.

    Article  PubMed  CAS  Google Scholar 

  192. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America-a randomized controlled trial. JAMA 2006; 295:761–775.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Massachusetts General Hospital, Boston, MA

    James B. Meigs MD, MPH (Senior Scientist)

Authors
  1. James B. Meigs MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Obesity, Diabetes, and Aging Research Center, University of South Florida College of Medicine, Tampa, FL

    Barbara Caleen Hansen PhD (Professor of Internal Medicine and Pediatrics Director) (Professor of Internal Medicine and Pediatrics Director)

  2. Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA

    George A. Bray MD (Boyd Professor) (Boyd Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Meigs, J.B. (2008). The Role of Obesity in Insulin Resistance. In: Hansen, B.C., Bray, G.A. (eds) The Metabolic Syndrome. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-116-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-116-5_3

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-738-9

  • Online ISBN: 978-1-60327-116-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation